YIH
VTGN icon

Y-Intercept (HK)’s VistaGen Therapeutics VTGN Stock Holding History

Y-Intercept (HK)’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-47,696
Closed -$89.2K – 1658
2023
Q2 		$89.2K Buy
+47,696
New +$167K 0.01% 1126

Other funds holding VTGN

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Y-Intercept (HK)'s VTGN Position: Q3 2023 in Review

Y-Intercept (HK) sold out of VistaGen Therapeutics (VTGN) in Q3 2023, closing a stake of 47,696 shares — an estimated $89.2K sold.

Y-Intercept (HK) first reported a position in VTGN in Q2 2023 and held it in 1 quarter. The position peaked at $89.2K in Q2 2023. 34 funds tracked by Wall St. Rank hold VTGN as of Q3 2023.

  • Y-Intercept (HK) reported no remaining VistaGen Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Y-Intercept (HK) sold 47,696 VistaGen Therapeutics shares in Q3 2023, an estimated $89.2K.
  • Y-Intercept (HK) first reported a position in VistaGen Therapeutics in Q2 2023 and held it in 1 quarter.
  • Y-Intercept (HK)'s VistaGen Therapeutics position peaked at $89.2K in Q2 2023.
  • 34 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2023.

Based on Y-Intercept (HK)'s 13F filing for Q3 2023, filed 14 Nov 2023.